Santen Pharmaceutical CoSNPHY 87 EBITDA Margin % is 30.21% as of Mar. 2026, which is 50% above its 10-year median of 20.10. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 75.5% on this metric.
Santen Pharmaceutical Co (OTCPK:SNPHY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Santen Pharmaceutical Co EBITDA Margin % Related Terms
Santen Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNPHY vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santen Pharmaceutical Co (SNPHY) has a EBITDA Margin % of 30.21% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Santen Pharmaceutical Co and its competitors. This is 50% above median its historical median of 20.10. Over the past decade, Santen Pharmaceutical Co's EBITDA Margin % has ranged from 4.64 to 24.34. According to the industry distribution chart, Santen Pharmaceutical Co ranks #234 out of 955 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Santen Pharmaceutical Co's EBITDA Margin % too high?
Santen Pharmaceutical Co's current EBITDA Margin % of 30.21% is 50% above median its 10-year median of 20.10. Over the past 10 years, this metric has ranged from a low of 4.64 to a high of 24.34. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Santen Pharmaceutical Co's value of 30.21% is 143.8% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #234 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #234 out of 955 companies for EBITDA Margin %. This places Santen Pharmaceutical Co in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Santen Pharmaceutical Co's value of 30.21% is 143.8% above this benchmark. Historically, Santen Pharmaceutical Co's own EBITDA Margin % has ranged from 4.64 to 24.34 over the past decade. While the company's 10-year median is 20.10 vs. the industry median of 12.39, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current EBITDA Margin % of 30.21% is 143.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current EBITDA Margin % is 30.21%, which is 50% above median its own 10-year median of 20.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $12.36 — trading 21.8% above its estimated fair value. The current EBITDA Margin % is 30.21%, which is 50% above median its 10-year median of 20.10 and 143.8% above the Drug Manufacturers industry median of 12.39. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current EBITDA Margin % is 30.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHY:
EBITDA Margin %: 30.21% (50% above median its 10-year median of 20.10)
GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
Industry Position: 143.8% above the Drug Manufacturers median (#234 of 955)
No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score
Get the complete analysis for SNPHY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHY has been successfully added to your 
